<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871310</url>
  </required_header>
  <id_info>
    <org_study_id>INQ/030815</org_study_id>
    <nct_id>NCT02871310</nct_id>
  </id_info>
  <brief_title>Vasoactive Effects of IQP-AS-118 in Healthy Individuals</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Monocenter, Crossover Investigation to Evaluate the Vasoactive Effects of IQP-AS-118 in Healthy Individuals: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InQpharm Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InQpharm Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the benefit of IQP-AS-118 on the vasoactive&#xD;
      effects in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study discontinued&#xD;
  </why_stopped>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in EndoPAT (chronic effect)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Pre-dose at the end vs. start of each intervention (week 4 vs. week 0 and week 12 vs. week 8, respectively) (inclusive of 4 weeks of wash-out period)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in EndoPAT (acute effect)</measure>
    <time_frame>12 weeks</time_frame>
    <description>3 h post-dose vs. pre-dose at start of each intervention (week 0 and week 8, respectively) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ex vivo blood platelet aggregation / adhesion (acute effect)</measure>
    <time_frame>12 weeks</time_frame>
    <description>3 h post-dose vs. pre-dose at start of each intervention (week 0 and week 8, respectively) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ex vivo blood platelet aggregation / adhesion pre-dose (chronic effect)</measure>
    <time_frame>12 weeks</time_frame>
    <description>End vs. start of each intervention (week 4 vs. week 0 and week 12 vs. week 8, respectively) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood coagulation / clotting parameters (acute effect)</measure>
    <time_frame>12 weeks</time_frame>
    <description>3 h post-dose vs. pre-dose at start of each intervention (week 0 and week 8, respectively) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood coagulation / clotting parameters predose (chronic effect)</measure>
    <time_frame>12 weeks</time_frame>
    <description>End vs. start of each intervention (week 4 vs. week 0 and week 12 vs. week 8, respectively) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global evaluation of benefit</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessed by the subjects and investigator at end of each intervention (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in SF- 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>End vs. start of each intervention (week 4 vs. week 0 and week 12 vs. week 8, respectively) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination</measure>
    <time_frame>12 weeks</time_frame>
    <description>End of each intervention vs. screening (Week 4 vs. screening, week 12 vs. screening) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>End vs. start of each intervention (Week 4 vs. week 0, week 12 vs. week 8) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>End vs. start of each intervention (Week 4 vs. week 0, week 12 vs. week 8) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>End vs. start of each intervention (Week 4 vs. week 0, week 12 vs. week 8) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Start and end of each intervention (Week 0, week 4, week 8 and week 12) (inclusive of 4 weeks of wash-out period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of tolerability</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessed by the subjects and investigator (4-point categorical scale) at week 4 and week 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Blood Flow</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>IQP-AS-118</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be taken once daily dosing of 1 tablet in the morning with 250 mL of water. The tablets should not be chewed, but swallowed whole.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>To be taken once daily dosing of 1 tablet in the morning with 250 mL of water. The tablets should not be chewed, but swallowed whole.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>IQP-AS-118</intervention_name>
    <description>1 tablet in the morning</description>
    <arm_group_label>IQP-AS-118</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet in the morning</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Caucasian males and females 45-65 years of age&#xD;
&#xD;
          2. Body mass index (BMI) of 25.0-29.9 kg/m2&#xD;
&#xD;
          3. Blood pressure (BP) at screening:&#xD;
&#xD;
               -  systolic blood pressure (SBP) ≤ 140 mmHg or&#xD;
&#xD;
               -  diastolic blood pressure (DBP) ≤ 90 mmHg&#xD;
&#xD;
          4. EndoPAT score: ≤ 2.00) at screening&#xD;
&#xD;
          5. Generally in good health, in particular an electrocardiogram (ECG) without&#xD;
             pathological findings at screening&#xD;
&#xD;
          6. Readiness to comply with study procedures, in particular:&#xD;
&#xD;
               -  Consumption of the investigational product (IP) / placebo according to&#xD;
                  investigator's advise&#xD;
&#xD;
               -  Maintaining the same level of physical activity and usual diet during the entire&#xD;
                  study&#xD;
&#xD;
               -  Accepting blood draws&#xD;
&#xD;
               -  Able to undergo an EndoPAT assessment&#xD;
&#xD;
               -  Complying with visits and all respective requirements for BP and EndoPAT&#xD;
                  measurements&#xD;
&#xD;
               -  Filling in diaries/questionnaires&#xD;
&#xD;
          7. Non-smoker since at least 6 months prior to screening and during the study&#xD;
&#xD;
          8. Stable body weight in the last 3 months prior to screening (&lt;3 kg self-reported&#xD;
             change) and during the study&#xD;
&#xD;
          9. Concomitant medications must have been stable at least during the last 1 month prior&#xD;
             to screening, if applicable&#xD;
&#xD;
         10. In women: postmenopausal for at least 12 months Participation is based upon written&#xD;
             informed consent form (ICF) by the participant following written and oral information&#xD;
             by the investigator regarding nature, purpose, consequences and possible risks of the&#xD;
             clinical study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known sensitivity to any components of the IP&#xD;
&#xD;
          2. Known primary or secondary hypertension or white-coat hypertension&#xD;
&#xD;
          3. Known impaired endothelial function as per investigator's judgement&#xD;
&#xD;
          4. Clinically significant disturbances in lipid metabolism e.g. known genetic&#xD;
             hyperlipidemia&#xD;
&#xD;
          5. Known type-1 / type-2-diabetes&#xD;
&#xD;
          6. Untreated or non-stabilized thyroid disorder&#xD;
&#xD;
          7. History and/or presence of clinically significant cardiovascular disease as per&#xD;
             investigator's judgement:&#xD;
&#xD;
               1. Known congenital heart defects&#xD;
&#xD;
               2. Myocardial infarction, heart failure, angina pectoris, life-threatening&#xD;
                  arrhythmia or stroke within the last 6 months prior to screening&#xD;
&#xD;
               3. Existing thrombosis or disposition to thrombosis&#xD;
&#xD;
          8. Any other known significant or serious condition / disease that renders subjects&#xD;
             ineligible, e.g.:&#xD;
&#xD;
               1. History of malignancy within ≤5 years prior to screening&#xD;
&#xD;
               2. Bleeding disorder and/or need for anticoagulants or anti-platelet agents&#xD;
&#xD;
               3. Current psychiatric care and/or use of neuroleptics&#xD;
&#xD;
               4. Bariatric surgery in the last 12 months prior to screening&#xD;
&#xD;
          9. Any known metabolic disease, gastrointestinal disorder or other clinically significant&#xD;
             disease/disorder which in the investigator's opinion could interfere with the results&#xD;
             of the study or the safety of the subject&#xD;
&#xD;
         10. Known arm lymphedema (e.g. due to mastectomy)&#xD;
&#xD;
         11. Other clinically relevant excursions of safety parameters or any other clinically&#xD;
             significant abnormality in hematology and/or biochemistry at the Investigator's&#xD;
             judgement&#xD;
&#xD;
         12. Dietary habits and/or restrictions that may affect the study outcome&#xD;
&#xD;
         13. Eating disorder or participation in a weight loss program&#xD;
&#xD;
         14. Use of medications (e.g. statins, renin angiotensin system inhibitors, nevibolol,&#xD;
             carvedilol, calcium channel blockers) or supplements that can influence vascular&#xD;
             endothelial function and/or blood flow (e.g. garlic, cocoa) within the last 4 weeks&#xD;
             prior to screening and during the study&#xD;
&#xD;
         15. Use of antiplatelet agents and / or anticoagulants (e.g. warfarin, acetylsalicylic&#xD;
             acid) within the last 4 weeks prior to screening and during the study&#xD;
&#xD;
         16. Use of medications or supplements that can influence SBP or DBP (e.g. ACE inhibitors,&#xD;
             diuretics, calcium channel, α- or ß-blockers, grape seed extract, coenzyme Q10 etc.)&#xD;
             within the last 4 weeks prior to screening and during the study&#xD;
&#xD;
         17. Use of lipid lowering medications (affecting lipid metabolism, platelet function or&#xD;
             antioxidant status, etc.) and/or dietary supplements (e.g. omega-3 fatty acids, green&#xD;
             tea extract, calcium, red yeast rice, phytosterols (incl. enriched products such as&#xD;
             e.g. Becel), niacin,, glucomannan or chitosan ) within the last 4 weeks prior to&#xD;
             screening and during the study&#xD;
&#xD;
         18. Use of medications that can influence cholesterol levels significantly (e.g.&#xD;
             corticosteroids, amiodarone, estrogen, anabolic steroids) according to investigator's&#xD;
             judgement&#xD;
&#xD;
         19. Use of weight loss treatment&#xD;
&#xD;
         20. Alcohol abuse (men: ≥21 units/week, women: ≥14 units/ week; 1 unit equals&#xD;
             approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)&#xD;
&#xD;
         21. Drug abuse&#xD;
&#xD;
         22. Reported participation in night shift work 2 weeks prior to screening and/or during&#xD;
             the study&#xD;
&#xD;
         23. Participation in another study or blood donation during the last 30 days prior to&#xD;
             screening and during the study&#xD;
&#xD;
         24. Any other reason deemed suitable for exclusion per investigator's judgment, e.g.&#xD;
             insufficient compliance with study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf Uebelhack</last_name>
    <role>Principal Investigator</role>
    <affiliation>analyze &amp; realize GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>analyze &amp; realize GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10369</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

